SIRPA and glioma: Furthermore, CD47 monoclonal antibody‐mediated phagocytosis requires the SLAMF7 signaling pathway,[27] as studies have shown that SIRPα expression in macrophages reduces CCL8 secretion by inhibiting Syk/Btk kinase activity, thereby impeding T cell recruitment and subsequent anti‐tumor responses.[28] Besides, CD47 antibody has been used to inhibit the development of glioma and showed no side effects to the nerve system.[29] These studies revealed that pairing the CD47 antibody with SLAMF7 might enhance tumor phagocytosis of macrophages rather than combining the SIRPα antibody with SLAMF7.